A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors

Inflammation Research

Volumn 45, Issue 2, 1996, Pages 68-74

  Brideau, C ^a   Kargman, S ^a   Liu, S ^a   Dallob, A L ^b   Ehrich, E W ^b   Rodger, I W ^a   Chan, C C ^a  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

CGP 28238; Cox 2 inhibitors; L 745,337; NS 398; SC 58125

Indexed keywords

5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; 5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; 6 (2,4 DIFLUOROPHENYLTHIO) 5 METHANESULFONAMIDO 1 INDANONE; ARACHIDONIC ACID; DICLOFENAC; FLOSULIDE; FLURBIPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; LIPOPOLYSACCHARIDE; MEFENAMIC ACID; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLBUTAZONE; PIROXICAM; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; SULINDAC; TENOXICAM; THROMBOXANE B2; TOLMETIN;

ARTICLE; BLOOD; BLOOD CLOTTING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DETERMINATION; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; MONONUCLEAR CELL; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONIC ACID; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; FEMALE; HUMANS; INDOMETHACIN; LIPOPOLYSACCHARIDES; MALE; THROMBOXANE B2;

EID: 0030022032     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02265118     Document Type: Article

References (39)

1. DeWitt DL, Smith WL. Primary structure of prostaglandin G/ H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci USA 1988;85:1412-6.
2. DeWitt DL, El-Harith EA, Kraemer SA, Andrews MJ, Yao EF, Armstrong RL, et al. The aspirin and heme-binding sites of ovine and murine prostaglandin endoperoxide synthases. J Biol Chem 1990;265:5192-8.
3. Yokoyama C, Tanabe T. Cloning of human gene encoding prostaglandin endoperoxide synthase and primary structure of the enzyme. Biochem Biophys Res Commun 1989;165: 888-94.
4. Xie WL, Robertson DL, Simmons DL. Mitogen-inducible prostaglandin G/H synthase: a new target for nonsteroidal antiinflammatory drugs. Drugs Dev Res 1992;25:249-65.
5. O'Neill GP, Kennedy BP, Mancini JA, Kargman S, Quellet M, Yergey J, et al. Selective inhibitors of Cox-2. In: Novel molecular approaches to anti-inflammatory therapy: Proceedings of the XIIth International Congress of Pharmacology, Inflammation Satellite Symposium; 1994 July 22-23; Toronto, (Ont.).
6. Smith WL, Marnett LJ. Prostaglandin endoperoxide synthases. Metal Ions Biol Syst 1994;30:163-99.
7. Herschman HR. Regulation of prostaglandin synthase-1 and prostaglandin synthase-2. Cancer Metastasis Rev 1994;13:241-56.
8. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991;266: 12866-72.
9. Lee SH, Soyoola E, Chanmugam P, Hart S, Sun W, Zhong H, et al. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem 1992;267:25934-8.
10. O'Sullivan MG, Huggins EM Jr, McCall CE. Lipopolysaccharide-induced expression of prostaglandin H synthase-2 in alveolar macrophages is inhibited by dexamethasone but not by aspirin. Biochem Biophys Res Commun 1993;191: 1294-300.
11. Kennedy BP, Chan C-C, Culp SA, Cromish WA. Cloning and expression of rat prostaglandin endoperoxide synthase (cyclooxygenase)-2 cDNA. Bicohem Biophys Res Commun 1993;197:494-500.
12. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994;91:3228-32.
13. Vane J R, Mitchell JA, Appleton I, Tomlinson A, Bishop-Bailey D, Croxtall J, et al. Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc Natl Acad Sci USA 1994;91:2046-50.
14. Harada Y, Hatanaka K, Saito M, Majima M, Ogino M, Kawamura M, et al. Detection of inducible prostaglandin H synthase-2 in cells in the exudate of rat carrageenin-induced pleurisy. Biomed Res 1994;15:127-30.
15. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993;268:6610-4.
16. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane RJ. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1994;90:11693-7.
17. Smith WL, Meade EA, DeWitt DL. Pharmacology of prostaglandin endoperoxide synthase isozymes-1 and -2. Ann NY Acad Sci 1994;714:136-42.
18. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995;55:2556-9.
19. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227: 680-5.
20. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979;76:4350-4.
21. Hadley JS, Fradin A, Murphy RC. Electron capture negative ion chemical ionization analysis of arachidonic acid. Biomed Environ Mass Spectrom 1988;15:175-8.
22. Martin TR, Mathison JC, Tobias PS, Leturcq DJ, Moriarty AM, Maunder RJ, et al. Lipopolysaccharide binding protein enhances the responsiveness of alveolar macrophages to bacterial lipopolysaccharide. J Clin Invest 1992;90:2209-19.
23. O'Sullivan MG, Huggins EM Jr, McCall CE. Lipopolysaccharide-induced expression of prostaglandin H synthase-2 in alveolar macrophages is inhibited by dexamethasone but not by aspirin. Biochem Biophys Res Comm 1993;191:1294-300.
24. Hempel SL, Monick MM, Hunninghake GW. Lipopolysaccharide induces prostaglandin H synthase-2 protein and mRNA in human alveolar macrophages and blood monocytes. J Clin Invest 1994;93:391-6.
25. Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A, et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980;17:317-27.
26. Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P, Catella F, Davi G, et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 1985;72:1177-84.
27. Osnes M, Larsen S, Eidsaunet W, Thom E. Effect of diclofenac and naproxen on gastroduodenal mucosa. Clin Pharmacol Ther 1979;26:399-405.
28. Fries JF, Williams CA, Bloch DA. The relative toxicity of nonsteroidal antiinflammatory drugs. Arth Rheum 1991;34: 1353-60.
29. Kaufman DW, Kelly JP, Sheehan JE, Laszlo A, Wiholm B-E, Alfredsson L, et al. Non steroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding. Clin Pharmacol Ther 1993;53:485-94.
30. Rodriguez LAG, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:769-72.
31. Langman MJS, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan RFA, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:1075-8.
32. Wiesenberg-Boettcher I, Schweizer A, Green JR, Mueller K, Maerki F, Pfeilschifter J. The pharmacological profile of CGP 28238, a novel highly potent anti-inflammatory compound. Drug Exp Clin Res 1989;15:501-9.
33. Gans KR, Galbraith W, Roman RJ, Haber SB, Kerr JS, Schmidt WK, et al. Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. J Pharmacol Exp Ther 1990;254:180-7.
34. Futaki N, Yoshikawa K, Hamasaka Y, Arai I, Higuchi S, Iizuka H, et al. NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmacol 1993;24:105-10.
35. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994;91:12013-7.
36. Chan CC, Boyce S, Brideau C, Ford-Hutchinson AW, Gordon R, Guay D, et al. Pharmacology of a selective cyclooxygenase-2 inhibitor L-745,337: a novel non-steroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and non-human primate stomach. J Pharmacol Exp Ther 1995; 274:1531-37.
37. Yeh KC. Pharmacokinetic overview of indomethacin and sustained-release indomethacin. Am J Med 1985;79:3-12.
38. Seideman P, Melander A. Equianalgesic effects of paracetamol and indomethacin in rheumatoid arthritis. Br J Rheumatol 1988;27:117-22.
39. Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, Iacobelli S, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 1994;271:1705-12.